The Sirona Dx Research and Development team is technology agnostic and works closely with our pharma clients to select the most appropriate methods and platforms. Our team applies cutting-edge technologies & a wide range of platforms in the development of high-complexity genomic assays.
Our Cancer Hotspot Panel allows the interrogation of hotspot regions of 50 oncogenes and tumor suppressor genes, with wide coverage of the KRAS, BRAF, and EGFR genes. This panel requires only 10 ng of DNA facilitating the sequencing of challenging samples like FFPE tissue.
We combine demanding clinical validation with the flexibility to customize assay parameters and reporting formats based on the sponsor's clinical study requirements. We use a variety of molecular approaches tailored to the client's needs, including Next Generation Sequencing, exome sequencing, bioinformatics, targeted resequencing, RT-PCR for gene expression, SNP analysis, and Capillary Electrophoresis. Our laboratory offers multiple platforms for the detection of mutations, copy number variations, and expression levels. Our extensive clinical validation guarantees robust performance and accuracy.